| Literature DB >> 23331553 |
Samira Ibrahim Korfali1, Tamer Hawi, Mohamad Mroueh.
Abstract
BACKGROUND: The consumption of dietary supplements is widely spread and on the rise. These dietary supplements are generally used without prescriptions, proper counseling or any awareness of their health risk. The current study aimed at analyzing the metals in 33 samples of imported dietary supplements highly consumed by the Lebanese population, using 3 different techniques, to ensure the safety and increase the awareness of the citizen to benefit from these dietary supplements.Entities:
Year: 2013 PMID: 23331553 PMCID: PMC3560192 DOI: 10.1186/1752-153X-7-10
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Characteristics of dietary tablets
| Vitamins | | | |
| V1 | Italy | healthy shiny hair | Niacin,Folic Acid, Vitamin B-12, Silica, |
| V2 | USA | Improve microcirculation | Vitamin C, E, Creatine, Ginseng cert |
| V3 | Belgium | physical and mental fatigue | Vitamin A, B6, B12, C, Ca, P, Zn, Cr |
| Vitamins and Minerals | | | |
| VM1 | UK | suitable for diabetics | Vitamin A,B1,B6, Folic acid, Fe, Zn, Mn, Se, Cu |
| VM2 | USA | essential nutrients and anti-oxidants | Vitamin D, Ca |
| VM3 | Denmark | Multivitamins and minerals for children | Vitamin A, B1,B12,D,E,Cu,Fe, Mn, Mo, Se, Zn, |
| VM4 | Italy | 13 vitamins and 13 minerals | Vitamin A, B1,B5, B6,B12,C,D,E, PP, Ca, Fe, Cr, Cu, Fe, K, Mn, Mo, Se, Zn |
| VM5 | USA | bones and teeth, prevent osteoporosis | Vitamin D3, Ca, magnesium silicate, mineral oil |
| VM6 | UK | Multivitamins and minerals for adults 50 | Multi-Vitamins,Ca, Cu, Fe,K, Ginkgo Biloba |
| VM7 | USA | Energizer multivitamin | Multi-Vitamins, Ca, Cu, Fe,Mo, B, K,, Ginseng, Ginkgo Biloba, Green Tea, Spinach, |
| VM8 | Switzerland | antioxidant effect, vitamin and mineral for vision and the eye | Beta-carotene, Vitamin B2, C, E, Cu, Se,Zn, Lutein |
| VM9 | USA | supports heart health | Multi-Vitamins,Ca, Cu, Fe,Mo, B, K,P, V,Se,Ti, |
| VM10 | UK | Mineral and Vitamins for pregnant women | Multi-Vitamins, Betacarotene, Cu,Fe, Zn |
| VM11 | USA | Vitamin, mineral, herb formula for women | Multi-Vitamins, Ca, Cu, Fe, B, K,P, Se |
| VM12 | USA | Vitamin, mineral, herb formula for men | Multi-Vitamins Ca, Cu, K, Mn, Se, Zn |
| VM13 | USA | Vitamins and mineral formula for pregnant and lactating women | Vitamin A,B1, B2,B6,B12,C,D,Folic acid, Ca, Mg, Zn, |
| Minerals | | | |
| M1 | USA | Calcium and Magnesium supplement | Ca- from calcium carbonate and oyster shells |
| M2 | USA | bones and help prevent osteoporosis | Ca, Mg, Zn, eggshells and mineral oil |
| M3 | USA | Calcium supplement | Ca, Mg, Cu, Mn |
| M4 | Italy | Food supplement with fossil coral | Ca, Mg, Fossil coral powder |
| M5 | UK | Helps maintain energy levels | Ca, Mg, Zn |
| M6 | USA | Promotes sleep, and calm mental and stress | Ca, Mg, Valerian |
| M7 | USA | Milk and dairy digestant | Lactase Enzyme,Soybean Oil |
| Herbs | | | |
| H1 | USA | Memory Disorder | Ginkgo Biloba (dried Leaf and powder) |
| H2 | USA | Digestive function | Pancreatin, Protease (Papain), Papaya Fruit Powder |
| H3 | UK | Immune system | Stearic acid, beta-carotene selenium yeast |
| H4 | USA | Immune function | Vegetable Stearic acid,and magnesium stearate, |
| H5 | Italy | Urinary ducts | Proanthocyandian, bearberry and ortosiphon leaves |
| H6 | Italy | Llight and moderate state of depression | L-Tryptophan, Vitamin PP, L-Tyrosine, L-Phenylalaninr, Vitamin B6 |
| H7 | USA | Support joint lubrication, | Hydrolized chicken sternal cartilage, Hyaluronic acid |
| H8 | Italy | metabolic process | Ginkgo Biloba leaves |
| H9 | USA | Memory Disorder | Ginkgo Biloba dried leaf and extract |
| H10 | Canada | Aids in digestion | Amylase, bromelain, papain, papaya |
Concentration of micronutrients with a high upper intake limit (Fe, Zn, Mn) in tablets compared to maximum accepted level, and daily intake (DI) as recommended on tablet label and compared to recommended daily allowance and permitted levels
| V1 | 1120 | 3841 | 3570 | 12245 | 328 | 1124 |
| V2 | 346 | 252 | 14 | 10 | 5.5 | 4 |
| V3 | 1836 | 2295 | 396 | 494 | 2.5 | 3 |
| VM1 | 9439 | 6513 | 9986 | 6890 | 2028 | 1399 |
| VM2 | 7659 | 12637 | 1918 | 3164 | 8.7 | 1396 |
| VM3 | 5801 | 5743 | 1199 | 1187 | 743 | 735 |
| VM4 | 11788 | 5894 | 5108 | 3554 | 1962 | 981 |
| VM5 | 36 | 55 | 3.5 | 5 | 17 | 25 |
| VM6 | 2420 | 4654 | 1839 | 2776 | 10 | 15 |
| VM7 | 9389 | 15117 | 2784 | 4482 | 1409 | 2269 |
| VM8 | 72 | 97 | 16054 | 21673 | 3.5 | 5 |
| VM9 | 41 | 62 | 3136 | 4705 | 852 | 1278 |
| VM10 | 21280 | 15534 | 9895 | 6566 | 132 | 96 |
| VM11 | 1942 | 8465 | 823 | 3586 | 361 | 1575 |
| VM12 | 35 | 128 | 1307 | 4731 | 639 | 2315 |
| VM13 | 13494 | 19162 | 5067 | 7195 | 43 | 62 |
| M1 | 82 | 253 | 2.1 | 7 | 63 | 196 |
| M2 | 24 | 31 | 961 | 1250 | 4.4 | 5.2 |
| M3 | 56 | 212 | 1263 | 4799 | 480 | 1826 |
| M4 | 58 | 186 | 3.5 | 11 | 14 | 45 |
| M5 | 6 | 24 | 806 | 3553 | 6.5 | 29 |
| M6 | 68 | 133 | 6.7 | 13 | 13 | 25 |
| M7 | 25 | 70 | 6.1 | 8 | 8.2 | 11 |
| H1 | 578 | 399 | 3.3 | 3 | 12 | 8 |
| H2 | 50 | 65 | 1.1 | 1.4 | 1.1 | 0.7 |
| H3 | 888 | 462 | 10.5 | 5.5 | 1.0 | 0.5 |
| H4 | 5 | 3 | 4452 | 2894 | 1.5 | 0.9 |
| H5 | 85 | 66 | 8.4 | 6.5 | 59 | 46 |
| H6 | 47 | 34 | 2.0 | 1.5 | 4.5 | 3 |
| H7 | 26 | 19 | 10.5 | 7.7 | 5.3 | 4 |
| H8 | 47 | 25 | 2.9 | 1.6 | 6.2 | 3 |
| H9 | 15 | 5 | 1.0 | 0.3 | 2.1 | 0.6 |
| H10 | 27 | 14 | 1.8 | 0.9 | 3.3 | 1.5 |
| MAL** | 1500a | - | 1500a | - | 250b | |
| PDE† | - | 15000 a | - | 15000 a | | 2500 b |
| RDA/FDA‡ | - | 8000 c | - | 8000 c (female) | - | - |
| 11000 c (male) | ||||||
| WHO/FAO‡‡ | - | 4800 d | - | 6000 e | - | - |
*DI: daily intake calculated from mass of tablet and labeled recommended tablets per day.
**MAL: Maximum accepted levels of metals in Tablets (μg/g)according to US Pharmacopeia (USP).
†PDE: Permitted Daily exposure (μg/day) according to US Pharmacopeia (USP).
‡RDA: Recommended daily allowance after FDA [6].
‡‡WHO/FAO : Permissible daily intake calculated from using provisional tolerable intake and body weight of 60 kg and 10% due to dietary supplements [35].
aUSP [20]b USP [34]c FDA [6]d JECFA [36]e JECFA [38].
Concentration of micronutrients with low established upper intake limit (Cu, Cr, Mo, Se) in tablets compared to maximum accepted level, and daily intake (DI) as recommended on tablet label and compared to recommended daily allowance and permitted levels
| V1 | 0.5 | 1.8 | 0.08 | 2.7 | 0.8 | 2.7 | 2.0 | 6.9 |
| V2 | 9.0 | 6.6 | 0.04 | 0.03 | 3.4 | 2.4 | 0.1 | 0.08 |
| V3 | 7.8 | 9.8 | 0.23 | 0.29 | 1.0 | 1.3 | 7.8 | 9.8 |
| VM1 | 1583 | 1092 | 5.5 | 2.4 | 7.7 | 5.3 | 60.1 | 41.4 |
| VM2 | 224 | 370 | 0.88 | 1.5 | 26 | 43 | 30.7 | 50.7 |
| VM3 | 185 | 183 | 0.58 | 0.58 | 4.1 | 4.0 | 13.8 | 15.5 |
| VM4 | 867 | 434 | 0.37 | 0.18 | 0.8 | 0.4 | 18.8 | 9.4 |
| VM5 | 9.5 | 14.3 | 0.07 | 0.11 | 0.6 | 0.9 | 1.0 | 1.5 |
| VM6 | 70 | 106 | 0.05 | 0.07 | 0.4 | 0.6 | 2.0 | 3.0 |
| VM7 | 867 | 1396 | 0.31 | 0.49 | 35.4 | 57 | 24.9 | 40 |
| VM8 | 1952 | 2635 | 0.02 | 0.03 | 13.3 | 18 | 52.9 | 71 |
| VM9 | 725 | 1087 | 1.26 | 1.89 | 44.4 | 67 | 12.8 | 19 |
| VM10 | 1270 | 927 | 0.17 | 0.12 | 0.5 | 0.4 | 0.9 | 0.7 |
| VM11 | 225 | 979 | 0.54 | 2.30 | 0.6 | 2.6 | 7.3 | 32 |
| VM12 | 281 | 1018 | 0.32 | 1.14 | 0.4 | 1.5 | 17.0 | 61 |
| VM13 | 1.1 | 1.42 | 0.03 | 0.05 | 0.6 | 0.8 | 4.0 | 5.7 |
| M1 | 6.9 | 22 | 0.06 | 0.20 | 0.7 | 2.2 | 2.1 | 6.2 |
| M2 | 6.5 | 8.5 | 0.15 | 0.19 | 0.5 | 0.7 | 0.5 | 0.7 |
| M3 | 376 | 1429 | 0.05 | 0.19 | 1.0 | 3.8 | 0.5 | 1.9 |
| M4 | 7.9 | 25 | 0.13 | 0.41 | 0.3 | 1.0 | 1.1 | 3.2 |
| M5 | 1.5 | 6.6 | 0.04 | 0.18 | 0.7 | 2.9 | 5.3 | 22 |
| M6 | 8.8 | 17 | 0.10 | 0.19 | 0.8 | 1.6 | 2.2 | 3.9 |
| M7 | 5.2 | 6.8 | 0.02 | 0.02 | 0.9 | 1.9 | 3.4 | 5.0 |
| H1 | 8.5 | 5.8 | 0.08 | 0.05 | 1.1 | 0.7 | 1.1 | 0.7 |
| H2 | 5.6 | 7.2 | 0.02 | 0.02 | 3.7 | 4.8 | 4.4 | 5.2 |
| H3 | 3.8 | 2.0 | 0.03 | 0.02 | 0.5 | 0.3 | 200 | 104 |
| H4 | 37 | 24 | 0.02 | 0.01 | 9.6 | 6.3 | 3.3 | 2.0 |
| H5 | 15 | 12 | 0.09 | 0.07 | 7.5 | 5.8 | 3.1 | 2.3 |
| H6 | 350 | 256 | 0.07 | 0.05 | 5.2 | 3.8 | 0.4 | 0.3 |
| H7 | 16.5 | 12 | 0.02 | 0.01 | 6.5 | 4.7 | 0.3 | 0.2 |
| H8 | 18.9 | 10 | 0.02 | 0.01 | 9.3 | 4.9 | 0.8 | 0.4 |
| H9 | 5.8 | 1.8 | 0.07 | 0.02 | 0.1 | 0.03 | 4.1 | 1.3 |
| H10 | 6.5 | 3.2 | 0.02 | 0.01 | 0.9 | 0.5 | 5.3 | 2.5 |
| MAL** | 100 a | | 15b | | 10 a | | 25c | |
| PDE† | | 1000 a | | 150 b | | 100 a | | 250 c |
| RDA/FDA‡ | | 900 d | | 35 d | | 34 d (male) | | 55 f |
| WHO/FAO‡‡ | 300 e | - | - | - |
*DI: daily intake calculated from mass of tablet and labeled recommended tablets per day.
**MAL: Maximum accepted levels of metals in Tablets (μg/g) according to US Pharmacopeia (USP).
†PDE: Permitted Daily exposure (μg/day) according to US Pharmacopeia (USP).
‡RDA: Recommended daily allowance after FDA [6].
‡‡WHO/FAO : Permissible daily intake calculated from using provisional tolerable intake and body weight of 60 and 10% due to dietary supplements [35].
aUSP [19]b USP [34]cUSP [20].
d FDA [6]e JECFA [38]f IOM [11].
Concentration of toxic metals (Pb, Hg, Cd, As) in tablets compared to maximum accepted level, and daily intake (DI) as recommended on tablet label and compared to recommended daily allowance and permitted levels
| V1 | 0.125 | 0.43 | 0.014 | 0.048 | 2.333 | 7.889 | 0.514 | 1.700 |
| V2 | 0.161 | 0.12 | 0.015 | 0.011 | 0.552 | 0.401 | 0.095 | 0.069 |
| V3 | 0.269 | 0.34 | 0.026 | 0.033 | 2.510 | 3.125 | 0.075 | 0.094 |
| VM1 | 0.126 | 0.09 | 0.035 | 0.024 | 2.914 | 2.001 | 0.477 | 0.345 |
| VM2 | 0.074 | 0.12 | 0.022 | 0.036 | 2.554 | 4.208 | 0.514 | 0.848 |
| VM3 | 0.074 | 0.07 | 0.021 | 0.021 | 0.881 | 0.871 | 1.621 | 1.800 |
| VM4 | 0.044 | 0.02 | 0.011 | 0.005 | 2.621 | 1.300 | 0.608 | 0.304 |
| VM5 | 0.086 | 0.13 | 0.550 | 0.831 | 0.319 | 0.482 | 0.115 | 0.174 |
| VM6 | 0.098 | 0.15 | 0.065 | 0.098 | 2.205 | 3.058 | 0.097 | 0.147 |
| VM7 | 0.045 | 0.07 | 0.045 | 0.072 | 2.131 | 3.431 | 0.606 | 0.310 |
| VM8 | 0.092 | 0.12 | 0.075 | 0.101 | 2.446 | 3.302 | 0.065 | 0.088 |
| VM9 | 0.067 | 0.10 | 0.115 | 0.173 | 2.326 | 3.489 | 0.254 | 0.381 |
| VM10 | 0.132 | 0.10 | 0.065 | 0.047 | 2.227 | 1.626 | 1.095 | 0.796 |
| VM11 | 0.067 | 0.29 | 0.038 | 0.166 | 1.921 | 8.371 | 0.086 | 0.375 |
| VM12 | 0.077 | 0.28 | 0.025 | 0.091 | 1.633 | 5.911 | 0.045 | 0.163 |
| VM13 | 0.096 | 0.14 | 0.082 | 0.114 | 0.107 | 0.152 | 0.574 | 0.815 |
| M1 | 0.071 | 0.22 | 0.093 | 0.278 | 0.821 | 2.537 | 0.013 | 0.038 |
| M2 | 0.029 | 0.04 | 0.055 | 0.072 | 2.516 | 3.271 | 0.034 | 0.045 |
| M3 | 0.071 | 0.27 | 0.044 | 0.167 | 1.820 | 6.916 | 0.057 | 0.217 |
| M4 | 0.41 | 1.29 | 0.078 | 0.249 | 0.222 | 0.638 | 0.014 | 0.046 |
| M5 | 0.012 | 0.05 | 0.015 | 0.066 | 2.139 | 9.433 | 0.068 | 0.300 |
| M6 | 0.13 | 0.25 | 0.025 | 0.049 | 2.534 | 4.850 | 0.035 | 0.068 |
| M7 | 0.097 | 0.13 | 0.044 | 0.054 | 0.196 | 0.143 | 0.066 | 0.089 |
| H1 | 0.206 | 0.14 | 0.121 | 0.083 | 2.551 | 1.760 | 0.047 | 0.034 |
| H2 | 0.109 | 0.14 | 0.255 | 0.329 | 1.493 | 1.922 | 0.055 | 0.071 |
| H3 | 0.039 | 0.02 | 0.095 | 0.049 | 0.143 | 0.074 | 0.466 | 0.242 |
| H4 | 0.247 | 0.16 | 0.085 | 0.055 | 0.540 | 0.351 | 0.699 | 0.454 |
| H5 | 0.269 | 0.21 | 0.351 | 0.270 | 2.473 | 1.902 | 0.012 | 0.009 |
| H6 | 0.029 | 0.02 | 0.243 | 0.175 | 0.294 | 0.288 | 0.023 | 0.017 |
| H7 | 0.005 | 0.01 | 0.027 | 0.020 | 0.834 | 0.609 | 0.032 | 0.023 |
| H8 | 0.045 | 0.02 | 0.011 | 0.006 | 0.599 | 0.317 | 0.076 | 0.040 |
| H9 | 0.271 | 0.09 | 0.098 | 0.031 | 0.096 | 0.031 | 0.056 | 0.018 |
| H10 | 0.058 | 0.03 | 0.011 | 0.005 | 0.086 | 0.042 | 0.022 | 0.011 |
| MAL** | 0.5 a | | 1.5 a | | 2.5 a | | 0.15 a | |
| PDE† | | 5 a | | 15 a | | 25 a | | 1.5 a |
| RDA/FDA‡ | | | | | | | | |
| WHO/FAO‡‡ | 21.4 b | 3.42 c | 6 d | 10 e |
*DI: daily intake calculated from mass of tablet and labeled recommended tablets per day.
**MAL: Maximum accepted levels of metals in Tablets (μg/g)according to US Pharmacopeia (USP).
†PDE: Permitted Daily exposure (μg/day) according to US Pharmacopeia (USP) for 50 kg body weight.
‡RDA: Recommended daily allowance after FDA [6].
‡‡WHO/FAO : Permissible daily intake calculated from using provisional tolerable intake and body weight of 60 kg and 10% due to dietary supplements [35].
aUSP [19]b JECFA [38]c JECFA [43]d JECFA [47]e JECFA [50].
Figure 1Samples above the maximum allowable Cd levels.
Figure 2Levels of As in samples composed of vitamins and minerals.
Figure 3Levels of As daily exposure in samples composed of vitamins and minerals.
Percent recovery of reference material by XRF (Expected Value)
| Tomato leave Certified (NIST 1573a) | 4.7 ± 0.14 | 368 ± 7 | 246 ± 8 | 14.89 ± 0.27 | - | 30.9 ± 0.7 |
| Measurement | 4.42 ± 0.18 | 371 ± 9 | 242 ± 10 | 13.12 ± 0.31 | - | 31.2 ± 0.8 |
| % Recovery | 94 | 101 | 98 | 88 | - | 101 |
| | | | | | | |
| Soil Certified (NIST 2586) | - | 51610 ± 890 | 1000 ± 18 | - | 6050 ± 660 | 352 ± 16 |
| Measurement | - | 48513 ± 700 | 903 ± 27 | - | 5627 ± 500 | 335 ± 20 |
| % Recovery | - | 94 | 90 | - | 93 | 95 |
Percent recovery of reference material by digestion (Expected values)
| Tomato leave Certified (NIST 1573a) | 0.112 ± 0.004 | 1.52 ± 0.04 | 1.99 ± 0.06 | 0.034 ± 0.004 | - |
| Measurement | 0.111 ± 0.008 | 1.55 ± 0.06 | 1.95 ± 0.05 | 0.033 ± 0.006 | - |
| % Recovery | 99 | 101 | 98 | 97 | - |
| | | | | | |
| Soil Certified (NIST 2586) | 8.7 ± 1.5 | 2.71 ± 0.54 | 301 ± 45 | 0.367 ± 0.038 | 432 ± 17 |
| Measurement | 7.9 ± 2.1 | 2.49 ± 0.47 | 268 ± 27 | 0.342 ± 0.027 | 411 ± 24 |
| % Recovery | 91 | 92 | 89 | 93 | 95 |